selective CDK2/4/6 inhibitor

oral agent in Ph. I/IIa for HR+ HER2- cancers

screen for CDK1/2 sel., SBDD + Free-Wilson

Journal of Medicinal Chemistry

Pfizer, San Diego, US


5. The Pfizer CDK2/4/6 inhibitor PF-60873600 is orally bioavailable with Ki values of 0.09 nM, 1.3 nM, and 0.16 nM for CDK2, CDK4, and CDK6, respectively, with lower activities…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: